BioMarin Pharmaceutical is to buy rare disease-focused Prosensa for $680m in cash and $160m in contingent milestones if Prosensa's Duchenne muscular dystrophy product – the GSK-reject drisapersen – is approved quickly in the US and Europe.
Drisapersen had been partnered with GlaxoSmithKline but the big pharma pulled out of the deal following drisapersen's failure in the...